Course of liver fibrosis in HIV-hepatitis C virus-coinfected patients depending on the response to hepatitis C therapy

AIDS Research and Human Retroviruses

Volumn 29, Issue 2, 2013, Pages 215-222

  Asensi, Víctor ^a   Cartón, José Antonio ^a   Collazos, Julio ^b   De La Fuente, Belén ^c  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b HOSPITAL DE GALDAKAO   (Spain)

^c HOSPITAL DE CABUEÑES   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A PLUS RIBAVIRIN; PEGINTERFERON ALPHA2B PLUS RIBAVIRIN;

ADULT; ALCOHOL ABUSE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HEPATITIS C; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER FIBROSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; OUTCOME ASSESSMENT; PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ADULT; ANTIVIRAL AGENTS; BIOPSY; COHORT STUDIES; COINFECTION; ELASTICITY IMAGING TECHNIQUES; FEMALE; HEPATITIS C, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84872960421     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2012.0108     Document Type: Review

References (26)

1. European Association for the study of the liver. EASL clinical practice guidelines: Management of hepatitis C virus infection. J Hepatol 2011;55:245-264.
2. Morgan TR, Ghany MG, Kim HY, et al.: Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 2010;52:833-844.
3. Castera L: Transient elastography and other noninvasive tests to assess hepatic fibrosis in patients with viral hepatitis. J Viral Hepat 2009;16:300-314.
4. Tsochatzis EA, Gurusamy KS, Ntaoula S, et al.: Elastography for the diagnosis of severity of fibrosis in chronic liver disease: A meta-analysis of diagnostic accuracy. J Hepatol 2011; 54:650-659.
5. Cartón JA, Collazos J, De la Fuente B, et al.: Factors associated with liver fibrosis in intravenous drug users coinfected with HIV and HCV. Antivir Ther 2011;16:27-35.
6. Carrión JA, Navasa M, Buti M, et al.: Hepatic elastography. Position paper of the Catalan Society of Gastroenterology. Gastroenterol Hepatol 2011;34:504-510.
7. Bedossa P and Poynard T: An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-293. (Pubitemid 26260021)
8. Goodman ZD: Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007; 47:598-607. (Pubitemid 47331757)
9. Martínez SM, Crespo G, Navasa M, and Forns X: Noninvasive assessment of liver fibrosis. Hepatology 2011;53: 325-335
10. Vergniol J, Foucher J, Castéra L, et al.: Changes of noninvasive markers and FibroScan values during HCV treatment. J Viral Hepat 2009;16:132-140.
11. Ogawa E, Furusyo N, Toyoda K, et al.: The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin. Antiviral Res 2009;83:127-134.
12. Macías J, del Valle J, Rivero A, et al.: Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirin. J Antimicrob Chemother 2010;65:2204-2211.
13. Hézode C, Castéra L, Roudot-Thoraval F, et al.: Liver stiffness diminishes with antiviral response in chronic hepatitis C. Aliment Pharmacol Ther 2011;34:656-663.
14. Ghany MG, Kleiner DE, Alter H, et al.: Progression of fibrosis in chronic hepatitis C. Gastroenterology 2003;124:97-104. (Pubitemid 36055343)
15. Ryder SD, Irving WL, Jones DA, et al.: Progression of hepatic fibrosis in patients with hepatitis C: A prospective repeat liver biopsy study. Gut 2004;53:451-455. (Pubitemid 38241346)
16. Marcolongo M, Young B, Dal Pero F, et al.: A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 2009;50:1038-1044.
17. Trépo E, Potthoff A, Pradat P, et al.: Role of a cirrhosis risk score for the early prediction of fibrosis progression in hepatitis C patients with minimal liver disease. J Hepatol 2011;55:38-44.
18. Macías J, Berenguer J, Japón MA, et al.: Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009;50:1056-1063.
19. Sulkowski MS, Mehta SH, Torbenson MS, et al.: Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007;21:2209-2216. (Pubitemid 350287219)
20. Lissen E, Clumeck N, Sola R, et al.: Histological response to pegIFNalpha-2a (40 KD) plus ribavirin in HIV-hepatitis C virus co-infection. AIDS 2006;20:2175-2181. (Pubitemid 44684708)
21. Bani-Sadr F, Lapidus N, Bedossa P, et al.: Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: Analysis of risk factors. Clin Infect Dis 2008;46:768-774. (Pubitemid 351321564)
22. Barreiro P, Labarga P, Martín-Carbonero L, et al.: Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIVcoinfected patients. Antivir Ther 2006;11:869-877. (Pubitemid 44736178)
23. Medrano J, Neukam K, Rallón N, et al.: Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfected with hepatitis C virus and HIV. Clin Infect Dis 2010;51:1209-1216.
24. Ingiliz P, Valantin MA, Preziosi P, et al.: Influence of interferon-based therapy on liver fibrosis progression in HIV/HCV coinfected patients: A retrospective repeated liver biopsy analysis. J Hepatol 2012;56:49-54.
25. Williams MJ, Lang-Lenton M, and the Trent HCV Study Group: Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infection. J Viral Hepat 2011;18:17-22.
26. Andersen ES, Moessner BK, Christensen PB, et al.: Lower liver stiffness in patients with sustained virological response 4 years after treatment for chronic hepatitis C. Eur J Gastroenterol Hepatol 2011;23:41-44.